NCT02195375View on ClinicalTrials.gov

Flutiform® Compared With Seretide® in the Treatment of COPD

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

923

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Flutiform 500/20 µg BID

DRUG

Flutiform 250/10 µg BID

DRUG

Seretide Accuhaler 50/500 µg BID

Trial Locations (5)

Unknown

Fitzroy

Beijing

Wellington

Seoul

Taipei

All Listed Sponsors
lead

Mundipharma Research Limited

INDUSTRY

NCT02195375 - Flutiform® Compared With Seretide® in the Treatment of COPD | Biotech Hunter | Biotech Hunter